Biocon Limited · NSE:BIOCON
Biocon — Fact Sheet (March 2004)
10 slides from Biocon's fact sheet, Mar 31, 2004
Slide 1: Financial Data Sheet for the Year Ended March 31, 2004
BIOCON LIMITED FINANCIAL DATA SHEET FOR THE YEAR ENDED MARCH 31, 2004 1
Slide 2: Table of Contents
TABLE OF CONTENTS BIOCON LIMITED: CONSOLIDATED FINANCIAL PERFORMANCE.............................. 3 PROFIT & LOSS STATEMENT...................................................................................... 3 BALANCE SHEET .........................................................................
Slide 3: Consolidated Financial Performance: Profit & Loss Statement
BIOCON LIMITED: CONSOLIDATED FINANCIAL PERFORMANCE PROFIT & LOSS STATEMENT Rs. million Variance Particulars FY2004 FY2003 (%) INCOME Sales 5,019 2,539 97.7 Contract research fees 387 278 39.3 Other income 87 16 438.4 Total 5,493 2,833 93.9 EXPENDITURE Manufacturing & other exp 3,697 2,092 76.8 Mfg /
Slide 4: Balance Sheet
BALANCE SHEET Rs. million BIOCON LIMITED BALANCE SHEET AS ON 31 MARCH 2004 Particulars As on 31 March 2004 As on 31 March 2003 SOURCES OF FUNDS Shareholder’s Funds 5,629 1,340 Share Capital 500 18 Reserves & Surplus 5,129 1,322 Deferred Tax Liability 177 143 Loan Funds 647 686 Secured Loans 472 582
Slide 5: Cash Flow Statement
CASH FLOW STATEMENT Rs. million BIOCON LIMITED CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH 2004 As on As on Particulars 31 March 2004 31 March 2003 I. Cash Flow from Operating Activities Net profit before tax 1,617 553 Less: non-cash items/ items required separately 178 222 Depreciation 164 137
Slide 6: Revenue Analysis: Business and Geographical Segments
REVENUE ANALYSIS BUSINESS SEGMENTS Rs. million FY2004 FY2003 Shift Rs. % Rs. % % Biopharmaceuticals (Biocon) 4,354 80.5 2,007 71.2 116.9 Statins* 3,028 56.0 1,199 42.5 152.5 Immunosuppressants 137 2.5 35 1.2 291.4 Others** 1,189 22.0 773 27.4 53.4 Enzymes (Biocon) 665 12.3 532 18.9 25.0 Research Ser
Slide 7: Top Customer Contribution and Key Ratios
TOP 10 CUSTOMER CONTRIBUTION Rs. million Revenues FY2004 FY2003 Biopharmaceuticals 47.4% 33.8% Enzymes 5.3% 8.2% Custom research 5.8% 7.5% KEY RATIOS FY2004 FY2003 PBIDT margin (%) 33% 26% PAT margin (%) 25% 15% RoCE (%) 50% 23% RoNW (%) 68% 39% Net worth (Rs. million) 5,742 1,340 7
Slide 8: Biocon Limited Standalone Profit & Loss Statement
BIOCON LIMITED STANDALONE PROFIT & LOSS STATEMENT Rs. million Variance Particulars FY2004 FY2003 (%) INCOME Sales 5,019 2,538 97.7 Contract research fees 6 5 22.9 Other income 87 17 405.8 Total 5,112 2,560 99.6 EXPENDITURE Manufacturing & other exp 3,483 1,914 81.9 Interest and finance charges 16 49
Slide 9: Syngene International Private Limited Profit & Loss Statement
SYNGENE INTERNATIONAL PRIVATE LIMITED PROFIT & LOSS STATEMENT Rs. million Variance Particulars FY2004 FY2003 (%) INCOME Contract research fees 319 225 41.8 Sale of compounds 60 36 63.0 Other income 1 1 26.9 Dividend income 5 - - Total 385 263 46.6 EXPENDITURE Contract research & other exp 201 164 23
Slide 10: Clinigene International Private Limited Profit & Loss Statement
CLINIGENE INTERNATIONAL PRIVATE LIMITED PROFIT & LOSS STATEMENT Rs. million Variance Particulars FY2004 FY2003 (%) INCOME Contract research fees 13 11 20.4 Total 13 11 20.4 EXPENDITURE Contract research & other exp 29 17 82.9 Interest and finance charges - - - Total 29 17 82.9 PBDT (16) (6) 216.9 De